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Introduction 
Synovial sarcoma accounts for 5% to 10% of malignant soft-tissue tumours. It occurs more 
commonly in males. Treatment options include surgery, radiotherapy and chemotherapy with the 
latter two being used in either an induction or adjuvant fashion. 
We review the 15-year experience of management of synovial sarcoma patients (2000-2015) 
referred to the East Midlands Sarcoma Service to allow for 5-year follow-up 
 
Methods 
Patients were identified from histopathology data held at Leicester and Nottingham. Data were 
stored in a secure Microsoft Excel spreadsheet. 
 
Results 
97 patients (49 male) were identified, mean age 42 years (range 8 – 83 years); data were incomplete 
on 3 patients. 51 (53%) arose in the lower limb. Size at presentation was 38 <5cm, 29 5-10cm and 28 
>10cm. 50 patients developed metastatic disease (7 presented with metastases) and 15 patients 
local recurrence over the course of treatment. The majority of patients were treated with surgery as 
the primary treatment modality although larger tumours received radiotherapy either as induction 
or adjuvant. Chemotherapy as a curative treatment was only used for small numbers of patients, 
although was more commonly used palliatively. 
 
Discussion 
Multi-modality treatment for synovial sarcomas is increasingly commonly used with a view to 
improving oncologic outcomes. In this unselected series of synovial sarcomas over 50% of patients 
relapse from the disease and appropriate targeting of those at high risk of relapse may offer a 
therapeutic advantage. Further work on the dataset continues to identify particular risk factors for 
relapse. 
